These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

828 related items for PubMed ID: 21802126

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Grass allergen tablet immunotherapy relieves individual seasonal eye and nasal symptoms, including nasal blockage.
    Durham SR, Riis B.
    Allergy; 2007 Aug; 62(8):954-7. PubMed ID: 17620075
    [Abstract] [Full Text] [Related]

  • 23. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial.
    Pfaar O, Wolf H, Klimek L, Schnitker J, Wüstenberg E.
    Clin Ther; 2012 Oct; 34(10):2072-81. PubMed ID: 23063373
    [Abstract] [Full Text] [Related]

  • 24. Sublingual immunotherapy with a standardised grass pollen extract; a double-blind placebo-controlled study.
    Hordijk GJ, Antvelink JB, Luwema RA.
    Allergol Immunopathol (Madr); 1998 Oct; 26(5):234-40. PubMed ID: 9885731
    [Abstract] [Full Text] [Related]

  • 25. Conjunctival provocation tests: a predictive factor for patients' seasonal allergic rhinoconjunctivitis symptoms.
    Kruse K, Gerwin E, Eichel A, Shah-Hosseini K, Mösges R.
    J Allergy Clin Immunol Pract; 2015 Oct; 3(3):381-6. PubMed ID: 25609338
    [Abstract] [Full Text] [Related]

  • 26. Changes in basophil activation during grass-pollen sublingual immunotherapy do not correlate with clinical efficacy.
    Van Overtvelt L, Baron-Bodo V, Horiot S, Moussu H, Ricarte C, Horak F, Zieglmayer P, Zieglmayer R, Montagut A, Galvain S, de Beaumont O, Le Gall M, Moingeon P.
    Allergy; 2011 Dec; 66(12):1530-7. PubMed ID: 21883279
    [Abstract] [Full Text] [Related]

  • 27. Sublingual immunotherapy in patients with allergic rhinoconjunctivitis caused by ragweed pollen.
    Skoner D, Gentile D, Bush R, Fasano MB, McLaughlin A, Esch RE.
    J Allergy Clin Immunol; 2010 Mar; 125(3):660-6, 666.e1-666.e4. PubMed ID: 20153030
    [Abstract] [Full Text] [Related]

  • 28. Increasing long-term safety of seasonal grass pollen sublingual immunotherapy: the ECRIT study.
    Sieber J, Neis M, Brehler R, Fölster-Holst R, Kapp A, Klimek L, Merk H.
    Expert Opin Drug Saf; 2012 Jan; 11(1):7-13. PubMed ID: 21980934
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. High-dose sublingual immunotherapy with single-dose aqueous grass pollen extract in children is effective and safe: a double-blind, placebo-controlled study.
    Wahn U, Klimek L, Ploszczuk A, Adelt T, Sandner B, Trebas-Pietras E, Eberle P, Bufe A, SLIT Study Group.
    J Allergy Clin Immunol; 2012 Oct; 130(4):886-93.e5. PubMed ID: 22939758
    [Abstract] [Full Text] [Related]

  • 32. Efficacy and safety of high-doses sublingual immunotherapy in ultra-rush scheme in children allergic to grass pollen.
    Stelmach I, Kaczmarek-Woźniak J, Majak P, Olszowiec-Chlebna M, Jerzynska J.
    Clin Exp Allergy; 2009 Mar; 39(3):401-8. PubMed ID: 19134016
    [Abstract] [Full Text] [Related]

  • 33. Sublingual Immunotherapy with a Five-Grass Pollen Tablet in Adult Patients with Allergic Rhinitis: An Open, Prospective, Noninterventional, Multicenter Study.
    Pfaar O, Richter HG, Klimek L, Sieber J, Hadler M, Karagiannis E.
    Biomed Res Int; 2015 Mar; 2015():584291. PubMed ID: 26351635
    [Abstract] [Full Text] [Related]

  • 34. Efficacy and safety of 5-grass pollen sublingual immunotherapy tablets in patients with different clinical profiles of allergic rhinoconjunctivitis.
    Malling HJ, Montagut A, Melac M, Patriarca G, Panzner P, Seberova E, Didier A.
    Clin Exp Allergy; 2009 Mar; 39(3):387-93. PubMed ID: 19134019
    [Abstract] [Full Text] [Related]

  • 35. [Sublingual immunotherapy in children with grass pollen induced allergic rhinoconjunctivitis].
    Wolthers OD, Høst A, Frederiksen B, Halken S.
    Ugeskr Laeger; 2012 Aug 27; 174(35):1989-92. PubMed ID: 22929576
    [Abstract] [Full Text] [Related]

  • 36. Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial.
    Kleine-Tebbe J, Ribel M, Herold DA.
    Allergy; 2006 Feb 27; 61(2):181-4. PubMed ID: 16409193
    [Abstract] [Full Text] [Related]

  • 37. Sublingual immunotherapy with grass pollen is not effective in symptomatic youngsters in primary care.
    Röder E, Berger MY, Hop WC, Bernsen RM, de Groot H, Gerth van Wijk R.
    J Allergy Clin Immunol; 2007 Apr 27; 119(4):892-8. PubMed ID: 17321581
    [Abstract] [Full Text] [Related]

  • 38. Randomized controlled trial of ragweed allergy immunotherapy tablet efficacy and safety in North American adults.
    Nolte H, Hébert J, Berman G, Gawchik S, White M, Kaur A, Liu N, Lumry W, Maloney J.
    Ann Allergy Asthma Immunol; 2013 Jun 27; 110(6):450-456.e4. PubMed ID: 23706715
    [Abstract] [Full Text] [Related]

  • 39. Efficacy and tolerability of high dose sublingual immunotherapy in patients with rhinoconjunctivitis.
    Worm M.
    Eur Ann Allergy Clin Immunol; 2006 Dec 27; 38(10):355-60. PubMed ID: 17274520
    [Abstract] [Full Text] [Related]

  • 40. Safety of specific sublingual immunotherapy with SQ standardized grass allergen tablets in children.
    Ibañez MD, Kaiser F, Knecht R, Armentia A, Schöpfer H, Tholstrup B, Bufe A.
    Pediatr Allergy Immunol; 2007 Sep 27; 18(6):516-22. PubMed ID: 17680910
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 42.